CureVac N.V. (CVAC)

Market Cap	558.54M
Revenue (ttm)	70.57M
Net Income (ttm)	-298.33M
Shares Out	224.31M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	855,543
Open	2.530
Previous Close	2.500
Day's Range	2.370 - 2.550
52-Week Range	2.215 - 6.300
Beta	2.61
Analysts	Hold
Price Target	10.00 (+301.61%)
Earnings Date	Nov 12, 2024

About CVAC

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for tre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 14, 2020
• Employees: 1,172
• Stock Exchange: NASDAQ
• Ticker Symbol: CVAC
• Website: https://www.curevac.com

Financial Performance

In 2023, CureVac's revenue was 53.76 million, a decrease of -20.26% compared to the previous year's 67.42 million. Losses were -260.17 million, 4.47% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 3 analysts, the average rating for CVAC stock is "Hold." The 12-month stock price forecast is $10.0, which is an increase of 301.61% from the latest price.

Price Target

$10.0

(301.61% upside)

Analyst Consensus: Hold